Antibody immunosuppressive therapy in solid organ transplant

Abstract

The use of antibodies in transplantation dates back to 1986 when muromonab CD3, a monoclonal antibody (mAb) targeting CD3, was first approved for prevention and treatment of renal allograft rejection. These agents have largely been used in a brief adjunctive manner to provide immunosuppression during the initial period after solid organ transplantation or during an episode of acute rejection. Recent advances in our understanding of transplant immunology have allowed emergence of numerous new mAbs, targeting co-stimulatory signals, cell surface receptors and novel protein constructs. During the next decade, transplant professionals will increasingly require knowledge of the mechanisms and pharmacologic characteristics of these novel therapeutic agents.

Key words:

• antibody
• immunosuppression
• transplantation
• biologics
• anti-adhesion

Note

Part I of this manuscript was previously published online at www.landesbioscience.com/journals/mabs/article/11159/

Mahumud N, Klipa D, Ahsan N. Antibody immunosuppressive therapy in solid-organ transplant: Part I mAbs 2010 2 148 156 http://dx.doi.org/10.4161/mabs.2.2.11159.

 Google Scholar

Figures and Tables

Figure 1 Mechanisms of T-cell activation and proliferation targeted by drugs. New agents in transplantation target various mechanisms of T-cell activation and proliferation with the intent to minimize calcineurin inhibitor use and improve long-term outcomes. CD, cluster of differentiation; MHC, major histocompatibility complex; NK, natural killer; PSGL, P-selectin glycoprotein ligand; sCR, soluble complement receptor; TCR, T-cell receptor.

Table 1 Drugs approved or in clinical studies for allograft rejection